Grit­stone con­tin­ues Covid-19 push with deal to de­vel­op 'self-am­pli­fy­ing RNA' vac­cines, as shares con­tin­ue bal­loon­ing

Grit­stone On­col­o­gy has had a big week, and it’s on­ly Wednes­day.

On Tues­day, the biotech re­vealed plans to start clin­i­cal test­ing of an ex­per­i­men­tal Covid-19 vac­cine — in tan­dem with NI­AID — that can al­so tar­get oth­er coro­n­avirus­es, with the goal of pre­vent­ing fu­ture pan­demics should SARS-CoV-2 prove dif­fi­cult to cure with cur­rent vac­cines. Then, on Wednes­day morn­ing, Grit­stone li­censed lipid nanopar­ti­cle tech­nol­o­gy from Genevant Sci­ences to de­vel­op what it’s call­ing “self-am­pli­fy­ing RNA vac­cines” against Covid-19.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER